Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 1.89 percent decrease over losses of $(0.53) per share from the same period last year.
Wells Fargo Initiates Coverage On Mohawk Industries with Equal-Weight Rating, Announces Price Target of $213
Wells Fargo analyst Deepa Raghavan initiates coverage on Mohawk Industries (NYSE:MHK) with a Equal-Weight rating and announces Price Target of $213.
